Business
Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments
Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments ...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nResverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY, Jan. 23, 2017\n\n\n\nSeveral Key Proteins That Drive Kidney (Renal) Disease and Dialysis Risk are Downregulated After a Single Dose of Apabetalone\n\n\n\nCALGARY, Jan. 23, 2017 /CNW/ - Resverlogix Corp. (\"Resverlogix\" or the \"Company\") (TSX: RVX) today announced preliminary results from the New Zealand based Phase 1 trial with severe kidney (renal) impaired patients. The data showed remarkable results in reducing inflamed protein biomarkers in patients with severe kidney impairment versus healthy control patients. It is believed that this is the first time in medical history that a direct connection of this type can be made between epigenetic regulation and its potential for positive disease impact. Both the healthy group and the severely impaired kidney group received equal amounts of apabetalone. \n\n\"It was shocking and highly encouraging to see the direct comparison of the protein data ranked by magnitude of effect in the two groups. For the first time, epigenetic and BET inhibition clinical data has been shown to differentially affect genes and proteins between advanced chronic kidney disease (CKD) patients and normal subjects,\" stated Donald McCaffrey, President and CEO.\n\nDr. Kamyar Kalantar-Zadeh, Chairman of the Renal Clinical Advisory Board and member of the BETonMACE Clinical Steering Committee stated, \"These early results help provide a first understanding of the potential rapid effects of BET inhibition and apabetalone on key proteins that drive risk and death in Stage 4 CKD and potentially dialysis patients. Late Stage 4-5 CKD and dialysis patients represent very important groups whom currently have limited therapeutic strategies that can improve their outcomes and quality of life,\" Dr. Kalantar-Zadeh added.\n\nOngoing expanded analysis of this exploratory data is also planned which will look at Ingenuity Pathway Analysis (IPA). The quick onse...